MDxHealth SA (MDXH.BR) Stock Price, Forecast & Analysis
Europe • Euronext Brussels • EBR:MDXH • BE0974461940
MDXH.BR Key Statistics, Chart & Performance
The current stock price of MDXH.BR is 3.02 EUR. In the past month the price increased by 5.19%. In the past year, price increased by 381.66%.
MDXH.BR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MDXH.BR. When comparing the yearly performance of all stocks, MDXH.BR is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
MDXH.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR. MDXH.BR has a bad profitability rating. Also its financial health evaluation is rather negative.
MDXH.BR Financial Highlights
Over the last trailing twelve months MDXH.BR reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -16.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.61% | ||
| ROE | -393.48% | ||
| Debt/Equity | 2.17 |
MDXH.BR Forecast & Estimates
9 analysts have analysed MDXH.BR and the average price target is 8.4 EUR. This implies a price increase of 178.05% is expected in the next year compared to the current price of 3.02.
For the next year, analysts expect an EPS growth of -6519.8% and a revenue growth 84.81% for MDXH.BR
MDXH.BR Ownership
MDXH.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.4 | 43.108B | ||
| ARGX | ARGENX SE | 27.16 | 43.046B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.737B | ||
| 2X1 | ABIVAX SA | N/A | 7.625B | ||
| ABVX | ABIVAX SA | N/A | 7.601B | ||
| GLPG | GALAPAGOS NV | N/A | 1.857B | ||
| GXE | GALAPAGOS NV | N/A | 1.853B | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| IVA | INVENTIVA SA | N/A | 963.467M | ||
| NANO | NANOBIOTIX | N/A | 868.079M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About MDXH.BR
Company Profile
MDxHealth SA is a BE-based company operating in Biotechnology industry. The company is headquartered in Herstal, Liege and currently employs 258 full-time employees. The company went IPO on 2006-06-26. MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Company Info
MDxHealth SA
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 258
Phone: 3243642070
MDxHealth SA / MDXH.BR FAQ
Can you describe the business of MDxHealth SA?
MDxHealth SA is a BE-based company operating in Biotechnology industry. The company is headquartered in Herstal, Liege and currently employs 258 full-time employees. The company went IPO on 2006-06-26. MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
What is the stock price of MDxHealth SA today?
The current stock price of MDXH.BR is 3.02 EUR. The price decreased by -3.76% in the last trading session.
Does MDxHealth SA pay dividends?
MDXH.BR does not pay a dividend.
What is the ChartMill rating of MDxHealth SA stock?
MDXH.BR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for MDxHealth SA?
MDxHealth SA (MDXH.BR) currently has 258 employees.
What is the ownership structure of MDxHealth SA (MDXH.BR)?
You can find the ownership structure of MDxHealth SA (MDXH.BR) on the Ownership tab.